ClinicalTrials.gg
RecruitingNCT07429305Updated Apr 8, 2026

Combined Tibial Nerve Stimulation and Standing for People With SCI

An interventional study of Standing + Tibial Nerve Stimulation in Spinal Cord Injury, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies in Spinal Cord Injuries by University of British Columbia — 16 open to participants now, 18 under way, none of them phase 3. Spinal Cord Injuries · University of British Columbia.

Planned enrollment
24th of 38
12 · median 22
Started
2026
with 4 others
No phase
31 of 44
13 open now
Primary completion
2026-12
later than 8 of 17 live
Registered
41st of 44
by date

Among the 44 studies in Spinal Cord Injuries by University of British Columbia, this one is the 24th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2026, is one of 31 with no phase, reaches primary completion later than 8 of the 17 other live ones, and was the 41st registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

16 of the 44 studies in Spinal Cord Injuries by University of British Columbia are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Spinal Cord Injuries by University of British Columbia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to understand how sensory inputs from the lower leg can influence pelvic floor muscle function and urogential function in adults with chronic spinal cord injury (SCI). The main questions it aims to answer are:

  1. What is the modulatory role of load and posture on reflex activation of the pelvic floor muscles in participants with SCI?
  2. What is the feasibility of combining tibial neuromodulation with standing therapy in participants with SCI?
  3. What are the potential effects of combined tibial neuromodulation and standing therapy on reflex excitability and urogential symptoms and quality of life in people with SCI?

Participants will be asked complete a series of assessments (questionnaires, electrophysiological testing) before and after a 12-week intervention of combined standing and tibial nerve stimulation therapy.

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • Spinal Cord Injury
  • Nerve Stimulation
  • Standing
  • Pelvic Floor
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 19 years of age
  • Have a SCI between C7 - T10 that occurred at least 12 months previously
  • Have a motor-complete or incomplete SCI (AIS A, B, C, or D)
  • Have symptoms of neurogenic LUT dysfunction
  • Meet the manufacture requirements for standing frame use (will be evaluated by the research team)
  • Are able to speak and understand English.

Exclusion criteria

Exclusion Criteria:

  • Have changed their bladder management program in the past month
  • Have received an injection of Botulinum toxin-A in any LUT structure in the past 2 weeks, or intend to receive an injection while participating in the trial
  • Have a non-stable SCI (e.g. spinal tumor)
  • Have signs of a lower motoneuron injury (e.g. cauda equina syndrome)
  • Have other neurological injury besides SCI
  • Have an implanted metallic or electronic device (e.g. pace maker, nerve stimulator)
  • Have a condition for which exercise or transcutaneous stimulation is
  • Have a severe acute medical issue that in the investigator's judgement would adversely affect the participant's participation in the study. Examples include, but are not limited to acute urinary tract infections, pressure sores, musculoskeletal injury, or unmanage blood pressure.
  • Are currently pregnant or have given birth within the past 12 months
  • Use walking as your primary means of movement around your home and the community.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Standing + Tibial Nerve Stimulation

    Behavioral: Standing + Tibial Nerve Stimulation

Interventions

  • BehavioralStanding + Tibial Nerve Stimulation

    Standing (with the support of a standing frame) combined with transcutaneous tibial nerve stimulation 3x/week for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Pelvic Floor Muscle Reflex Excitability

    We will electrically stimulate the tibial nerve and record reflexes responses from the pelvic floor muscles using perianal surface electromyography. We will examine the amplitude of the reflex response.

    Time frame: At baseline to within 2 weeks of completing the study intervention

Secondary outcomes

  1. Feasibility - Recruitment Rate

    Recruitment rate will be evaluated by number of participants approached, screened for eligibility, as well as reasons for exclusions.

    Time frame: Through study completion, an average of 8 months

  2. Feasibility - Adherence

    Adherence will be tracked by the compliance of participants to the intervention, with reasons for missed sessions or drop-outs noted.

    Time frame: Through study completion, an average of 8 months

  3. Feasibility - Adverse Events

    Any adverse events to study protocols will be recorded.

    Time frame: Through study completion, an average of 8 months

  4. Acceptability

    The acceptability of the intervention will be evaluated using a 7-point Likert scale to rate participants' opinions about the intervention (enjoyment and perceived benefits) and the outcome measures (tolerability and appropriateness of the measurement procedures). A higher score indicates a more acceptable intervention.

    Time frame: Through study completion, an average of 3 months

  5. Neurogenic Bladder Symptoms Score (NBSS)

    Participants will be asked to respond to 24 questions regarding the severity of their bladder symptoms secondary to neurological injury. Questions cover three subdomains: incontinence, storage and voiding, and consequences. The total score on this questionnaire ranges from 0-74, where a lower score represents less severe symptoms.

    Time frame: Through study completion, an average of 8 months

  6. Incontinence Quality of Life Questionnaire (I-QoL)

    Participants will be asked to respond to 22 questions about how urinary incontinence impacts their quality of life using a 5-point scale with values ranging from 1 (extremely) to 5 (not at all). The questionnaire probes three subdomains of how incontinence may affect quality of life: avoidance and limiting behavior, psychosocial impact, and social embarrassment. Total score on this questionnaire ranges from 0-100, where a higher score represents higher quality of life.

    Time frame: Through study completion, an average of 8 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Dec 2026, 8 months later.

Of 791 non-industry interventional studies with no phase under Spinal Cord Injuries, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 65. This study's planned 8 months is below that.

Counting every sponsor, half of 840 studies reached it within 36 months; a quarter within 17 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 24, 2026
StartEst.
Apr 2, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07429305
Collaborators
The Craig H. Neilsen Foundation
Responsible party
Tania Lam (Professor, University of British Columbia) — Principal investigator
First posted
Feb 24, 2026
Start date
Apr 2, 2026 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Yao Sun, PhD
Contact
lamlab@icord.org
604-675-8815

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion